{
    "clinical_study": {
        "@rank": "46999", 
        "arm_group": {
            "arm_group_label": "No intervention", 
            "description": "No intervention- this is an observational study of patients receiving Infliximab."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine which early infliximab pharmacokinetic level is\n      most associated with clinical remission at weeks 30 and 54 in pediatric IBD patients."
        }, 
        "brief_title": "Individualized Infiximab Dosing-Proof of Concept Study", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Inflammatory Bowel Diseases", 
        "condition_browse": {
            "mesh_term": [
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Our aims are:\n\n        1. to determine which early pk level; week 6 (peak), week 8 (2 week) or week 14 (trough),\n           is most associated with week 30 and  54 outcomes in pediatric IBD patients.\n\n        2. to determine if the forecasted PK determined by a newly developed Population PK Model\n           software program is in agreement with the observed PK in IBD patients receiving\n           infliximab.\n\n      Subject recruitment is limited to patients of the principal investigator only. Subjects will\n      be approached for participation in the research in person during a routine clinic visit by a\n      member of the study team."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and females on IFX\n\n          2. Patients with IBD\n\n          3. Age 6-23\n\n          4. Able to obtain consent\n\n        Exclusion Criteria:\n\n          1. Not receiving infliximab\n\n          2. On 10 mg/kg of IFX\n\n          3. Not able to obtain consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "23 Years", 
            "minimum_age": "6 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Males and females patients age 6 to 23"
            }
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027727", 
            "org_study_id": "Infiximab Dosing"
        }, 
        "intervention": {
            "arm_group_label": "No intervention", 
            "description": "no intervention- tihs is an observational study", 
            "intervention_name": "No Intervention", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "inflammatory bowel disease", 
            "infliximab", 
            "trough level", 
            "crohn's disease", 
            "ulcerative colitis"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "contact": {
                "email": "namita.singh@cshs.org", 
                "last_name": "Namita Singh, MD", 
                "phone": "310-423-7100"
            }, 
            "contact_backup": {
                "email": "silvia.callejas@cshs.org", 
                "last_name": "Silvia E Callejas, RNC", 
                "phone": "3102486937"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90048"
                }, 
                "name": "Cedars Sinai Medical Center"
            }, 
            "investigator": {
                "last_name": "Marla Dubinsky, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Individualized Infiximab Dosing-Proof of Concept Study", 
        "overall_official": {
            "affiliation": "Cedars-Sinai Medical Center", 
            "last_name": "Marla Dubinsky, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Determine what level (peak, 2 week or trough) best correlates with clinical remission at week 54\nClinical remission definition: PCDAI < 10 or CDAI < 150 for Crohn's disease, or partial Mayo <2 points and no sub-score > 1 for ulcerative colitis.\nFischer exact testing will be done to determine what detectable IFX level (week 6, week 8 or week 14) is most associated with week 54 clinical remission.\nWilcoxon rank sum test will be performed to determine the median level that is most associated with week 54 clinical remission.\nRegression tree analysis will be performed to determine the optimal infliximab level cut point that predicts week 54 clinical remission.", 
                "measure": "Infliximab level and clinical remission at 54 weeks", 
                "safety_issue": "No", 
                "time_frame": "54 weeks"
            }, 
            {
                "description": "Determine what level (peak, 2 week or trough) best correlates with clinical remission at week 30\nClinical remission definition: PCDAI < 10 or CDAI < 150 for Crohn's disease, or partial Mayo <2 points and no sub-score > 1 for ulcerative colitis.", 
                "measure": "Infliximab level and clinical remission at 30 weeks", 
                "safety_issue": "No", 
                "time_frame": "30 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027727"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cedars-Sinai Medical Center", 
            "investigator_full_name": "Marla Dubinsky", 
            "investigator_title": "Director of Pediatrics IBD Center, Cedars Sinai Med Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Secondary outcomes\nAgreement between pk profiles predicted by  the PK model and actual (measured)  pk profiles for all patients with at least 6 months in between levels Analysis: Bland Altman test will be used to quantify the agreement between the two methods: Software pk model vs actual measured pk profiles\nComparison of software selected dose regimens with actual dose regimens for cost and overall drug exposure (AUC and Cmax)", 
            "measure": "Agreement between pk profiles predicted by  the PK model and actual (measured)  pk profiles", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Cedars-Sinai Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cedars-Sinai Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}